JP2019527706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527706A5 JP2019527706A5 JP2019506349A JP2019506349A JP2019527706A5 JP 2019527706 A5 JP2019527706 A5 JP 2019527706A5 JP 2019506349 A JP2019506349 A JP 2019506349A JP 2019506349 A JP2019506349 A JP 2019506349A JP 2019527706 A5 JP2019527706 A5 JP 2019527706A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- protein
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374621P | 2016-08-12 | 2016-08-12 | |
| US62/374,621 | 2016-08-12 | ||
| PCT/EP2017/070513 WO2018029367A1 (en) | 2016-08-12 | 2017-08-11 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527706A JP2019527706A (ja) | 2019-10-03 |
| JP2019527706A5 true JP2019527706A5 (enExample) | 2020-09-24 |
| JP7573365B2 JP7573365B2 (ja) | 2024-10-25 |
Family
ID=59686928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019506349A Active JP7573365B2 (ja) | 2016-08-12 | 2017-08-11 | 癌の併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180118832A1 (enExample) |
| EP (1) | EP3497130B1 (enExample) |
| JP (1) | JP7573365B2 (enExample) |
| KR (3) | KR20250028537A (enExample) |
| CN (1) | CN109641963A (enExample) |
| AU (2) | AU2017310027A1 (enExample) |
| BR (1) | BR112019001818A2 (enExample) |
| CA (1) | CA3031168A1 (enExample) |
| CL (1) | CL2019000277A1 (enExample) |
| ES (1) | ES2905663T3 (enExample) |
| IL (1) | IL264730B2 (enExample) |
| MX (1) | MX2019001503A (enExample) |
| PH (1) | PH12019500270A1 (enExample) |
| RU (1) | RU2019106663A (enExample) |
| SG (1) | SG11201901126UA (enExample) |
| WO (1) | WO2018029367A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CA3094500A1 (en) * | 2018-03-23 | 2019-09-26 | The University Of Western Australia | Method for immunotherapy drug treatment |
| BR112020022145A2 (pt) * | 2018-05-04 | 2021-01-26 | Merck Patent Gmbh | inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer |
| BR112020021082A2 (pt) * | 2018-05-15 | 2021-02-17 | Merck Patent Gmbh | regimes de dosagem para inibição de tgf-b direcionada para uso no tratamento de câncer em indivíduos sem tratamento prévio |
| CA3103245A1 (en) * | 2018-06-13 | 2019-12-19 | Merck Patent Gmbh | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
| JP2021529777A (ja) * | 2018-07-02 | 2021-11-04 | メルク パテント ゲーエムベーハー | 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法 |
| CN112672753B (zh) * | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| MX2021005823A (es) * | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. |
| SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| EP3693974A1 (en) * | 2019-02-07 | 2020-08-12 | Koninklijke Philips N.V. | Identifying responsiveness to radio-immuno combination therapy |
| KR102815892B1 (ko) | 2019-06-10 | 2025-06-04 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도 |
| EP3990116A1 (en) * | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN112442132A (zh) * | 2019-09-05 | 2021-03-05 | 复旦大学 | 靶向肿瘤的重组双功能融合蛋白及其应用 |
| WO2021061437A1 (en) * | 2019-09-12 | 2021-04-01 | Sirnaomics, Inc. | CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| JP7495489B2 (ja) | 2019-10-21 | 2024-06-04 | ナンチン リーズ バイオラブス カンパニー，リミティド | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 |
| US20230044248A1 (en) * | 2019-11-01 | 2023-02-09 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| US20230340122A1 (en) * | 2019-11-05 | 2023-10-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| CA3158047A1 (en) * | 2019-12-11 | 2021-06-17 | Yunying CHEN | Bi-functional antibody against pd-l1 and tgf? |
| EP3838260A1 (en) | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
| WO2021123432A1 (en) | 2019-12-20 | 2021-06-24 | Ares Trading S.A. | Igg:tgfbetarii fusion protein composition |
| CA3167427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CN115175942B (zh) * | 2020-02-25 | 2025-05-30 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
| AU2021256925A1 (en) * | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| EP4194002A4 (en) * | 2020-07-24 | 2024-08-14 | Mabwell (Shanghai) Bioscience Co., Ltd. | TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| CN114984204A (zh) * | 2021-03-02 | 2022-09-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN117015394A (zh) * | 2021-03-12 | 2023-11-07 | 博际生物医药科技(杭州)有限公司 | 结合人TGFβ和PD-L1的双功能分子及其应用 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| US20250281633A1 (en) | 2021-05-03 | 2025-09-11 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
| US20240226319A1 (en) | 2021-05-25 | 2024-07-11 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| GB202215997D0 (en) * | 2022-10-28 | 2022-12-14 | Io Biotech Aps | Therapy |
| CN120418286A (zh) | 2023-01-09 | 2025-08-01 | 北京拓界生物医药科技有限公司 | TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途 |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
-
2017
- 2017-08-11 JP JP2019506349A patent/JP7573365B2/ja active Active
- 2017-08-11 BR BR112019001818A patent/BR112019001818A2/pt not_active Application Discontinuation
- 2017-08-11 US US15/674,655 patent/US20180118832A1/en not_active Abandoned
- 2017-08-11 RU RU2019106663A patent/RU2019106663A/ru unknown
- 2017-08-11 KR KR1020257005808A patent/KR20250028537A/ko active Pending
- 2017-08-11 ES ES17755458T patent/ES2905663T3/es active Active
- 2017-08-11 CN CN201780049391.8A patent/CN109641963A/zh active Pending
- 2017-08-11 CA CA3031168A patent/CA3031168A1/en active Pending
- 2017-08-11 AU AU2017310027A patent/AU2017310027A1/en not_active Abandoned
- 2017-08-11 MX MX2019001503A patent/MX2019001503A/es unknown
- 2017-08-11 KR KR1020197006703A patent/KR20190039200A/ko not_active Ceased
- 2017-08-11 WO PCT/EP2017/070513 patent/WO2018029367A1/en not_active Ceased
- 2017-08-11 IL IL264730A patent/IL264730B2/en unknown
- 2017-08-11 EP EP17755458.1A patent/EP3497130B1/en active Active
- 2017-08-11 KR KR1020237028359A patent/KR20230125859A/ko not_active Ceased
- 2017-08-11 SG SG11201901126UA patent/SG11201901126UA/en unknown
-
2019
- 2019-02-01 CL CL2019000277A patent/CL2019000277A1/es unknown
- 2019-02-07 PH PH12019500270A patent/PH12019500270A1/en unknown
-
2021
- 2021-06-24 US US17/357,380 patent/US20220017621A1/en not_active Abandoned
-
2024
- 2024-09-06 AU AU2024219446A patent/AU2024219446A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019106663A (ru) | Комбинированная терапия рака | |
| Bianco et al. | Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide | |
| JP2017506217A5 (enExample) | ||
| JP2018508512A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2020514290A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2016527286A5 (enExample) | ||
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| JP2011103891A5 (enExample) | ||
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| JP2020517658A5 (enExample) | ||
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| JP2021511372A5 (enExample) | ||
| Pirker et al. | Cetuximab in non-small-cell lung cancer | |
| JP2016504420A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JPWO2022270524A5 (enExample) |